Will tarloxotinib finally break the HER2 barrier in lung cancer?

(University of Colorado Anschutz Medical Campus) By pairing a potent HER2/EGFR inhibitor with a targeting mechanism specific to tumors, researchers show that tarloxotinib is far more active against HER2 lung cancer cell lines than even the most successful existing HER2/EGFR inhibitors.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news